Palvella Therapeutics (NASDAQ:PVLA) Earns “Buy” Rating from HC Wainwright

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $38.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 125.12% from the stock’s current price.

PVLA has been the topic of a number of other research reports. Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. TD Cowen assumed coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They set a “buy” rating and a $44.00 price objective on the stock.

Palvella Therapeutics Stock Up 4.5 %

NASDAQ PVLA opened at $16.88 on Tuesday. The company’s 50-day moving average price is $13.30. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32. The stock has a market capitalization of $189.39 million, a P/E ratio of -1.40 and a beta of 0.68.

Insider Activity

In related news, Director George M. Jenkins acquired 4,000 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were purchased at an average cost of $12.93 per share, with a total value of $51,720.00. Following the completion of the purchase, the director now owns 180,671 shares of the company’s stock, valued at $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.39% of the company’s stock.

Institutional Trading of Palvella Therapeutics

An institutional investor recently bought a new position in Palvella Therapeutics stock. Geode Capital Management LLC bought a new position in Palvella Therapeutics (NASDAQ:PVLA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,270 shares of the company’s stock, valued at approximately $171,000. Geode Capital Management LLC owned about 0.13% of Palvella Therapeutics at the end of the most recent reporting period. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.